Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus ...(redictions of the future are forward-loo...),Health

Date:11/24/2008

redictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from further preclinical studies and clinical trials may not correlate to the initial preclinical results, the risk that bavituximab will not achieve broad-spectrum anti-viral effects and the risk that anti-PS antibodies will not be less susceptible to viral mutations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended July 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim Bi
'/>"/>
SOURCE  Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related medicine news :

1. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
2. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
3. Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration
4. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
5. International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer
6. MultiVu Video Feed: NEW RESEARCH PUBLISHED IN THE AMERICAN JOURNAL OF CLINICAL NUTRITION FINDS PISTACHIOS IMPROVE RISK FACTORS FOR HEART DISEASE
7. McCulley/Cuppan Consultants Contribute Chapter to the Newly Published Book, Rhetoric of Healthcare: Essays Toward a New Disciplinary Inquiry
8. Notice of Proposed Rulemaking on U.S. Department of Labors Risk Assessment Procedures Published in Federal Register
9. Positive Findings Published on Emergent Technology for Treating Chronic Pain
10. Study Published in JAMA on RFID Interference Ignores Real-World Use Cases, According to SkyeTek
11. Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer